ClinicalTrials.gg
RecruitingNCT07264543Updated Mar 27, 2026

Early Methylene Blue in the Microhemodynamics of Septic Patients

A Phase 2/3 interventional study of Methylene blue infusion in Septic Shock and Hypoperfusion, sponsored by Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing Methylene Blue in Shock, Septic — 2 open to participants now, 2 under way, 2 of them phase 3. Methylene Blue · Shock, Septic.

Planned enrollment
8th of 11
50 · median 88
Started
2026
the only one that year
Phase 2/3
3 of 11
2 open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva

Among the 11 studies testing Methylene Blue in Shock, Septic, this one is the 8th largest by planned enrollment, is the only one that started in 2026, is one of 3 in phase 2/3, and was the 11th registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

2 of the 11 studies testing Methylene Blue in Shock, Septic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Methylene Blue

Methylene Blue: first FDA approval 2016 (PROVAYBLUE), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Methylene Blue in Shock, Septic, or all of them as a file.
02

Study summary

The aim of the study is to evaluate the viability and feasibility of its protocol in order to conduct a larger clinical trial to assess whether methylene blue can improve patient-centered clinical outcomes such as mortality or length of hospital stay in septic shock patients.

Read the detailed description

One of the primary causes of high mortality in patients with septic shock is microcirculatory dysfunction related to vasodilation caused by excessive oxide nitric production. It has been shown that methylene blue, an old and safe drug that can reduce vasodilation by blocking nitric oxide pathways, is a vasopressor-sparing treatment in sepsis. Nevertheless, there is no evidence that methylene blue improves patient-centered clinical outcomes such as mortality. Understanding how early methylene blue affects the microhemodynamics of septic shock patients may lead to relevant clinical results that can improve their prognosis. So, the objective of the study is to evaluate the viability and feasibility of the study protocol for a larger clinical trial, assessing the effectiveness of early methylene blue in the microhemodynamics of septic shock patients, mainly through the capillary refill time measurement. For this purpose, a pilot study of an open-label, randomized, controlled and single-center clinical trial will be conducted, with two treatment arms: the intervention group (methylene blue plus standard treatment) and the control group (standard treatment). Fifty adult patients with septic shock within the first six hours of diagnosis will be included in this study. They will be randomized to either receive a methylene blue infusion or not. The randomization will be conducted using RedCap with a 1:1 ratio and variable block sizes. The primary outcome will be to assess the feasibility, which is defined as completing the study recruitment within the 12-month timeline and achieving protocol adherence of 90% or higher. Comparisons between groups for serially measured micro and macrohemodynamics parameters will be the secondary outcomes. Additionally, the incidence of adverse events related to methylene blue will be monitored.

03

Conditions studied

  • Septic Shock
  • Hypoperfusion

Browse trials for

Keywords

  • Septic Shock
  • Methylene Blue
  • Microcirculation
  • Capillary Refill Time
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with a diagnosis of sepsis and persistent hemodynamic dysfunction despite adequate fluid resuscitation, requiring escalation of noradrenaline dose to maintain mean arterial pressure ≥65 mmHg, with prolonged capillary refill time or septic shock according to Sepsis-3 definition, within less than 6 hours of the diagnosis, will be eligible for the study.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding patients;
  • Patients with any withdrawal or withholding life-sustaining intervention;
  • Cardiac surgery patients in the immediate postoperative period;
  • septic shock, with a high propability of death within 24 hours;
  • Personal or familiar history of glucose-6-phosphate dehydrogenase (G6PD) deficiency;
  • Allergy to methylene blue, phenothiazines, or food dyes;
  • Recent administration of linezolid (less than 14 days ago);
  • Recent intake of serotonergic psychiatric medications (less than 2 weeks ago - with the exception of fluoxetine, which must be less than 5 weeks ago),
  • Recent intake (less than 2 weeks ago) of monoamine oxidase inhibitors (MAOIs), such as rasagiline and selegiline.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Methylene blue group

    The intervention group will receive methylene blue plus standard treatment for septic shock, according to the international guidelines.

    Drug: Methylene blue infusion

  • No intervention
    Control group

    The control group will receive the standard treatment according to international guidelines for the management of sepsis and septic shock.

Interventions

  • DrugMethylene BlueStudies of Methylene BlueMethylene Blue pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Methylene blue at a dose of 100mg (diluted in 100ml of 5% dextrose solution) in continuous infusion for 06 hours per day, for 03 days, plus standard treatment according to international guidelines for the management of sepsis and septic shock. The 03 consecutive MB infusions, each lasting 06 hours, will be performed every 24 hours, starting from randomization: the first infusion at T0, the second at T24, and the third at T48, considering T0 the moment after the patient randomization into the study. The interruption of the protocol will be recommended if vasopressors are completely discontinued during the three days of methylene blue infusion. The attending physician may discontinue methylene blue treatment if judges necessary. Similarly, interruption may occur if the family or patient request.

    Also known as: Methylene blue, Phenothiazines

06

What researchers measure

Primary outcomes

  1. To evaluate the feasibility of the study protocol.

    The primary outcome of the study is to evaluate feasibility, defined as completing the study protocol according to the planned timeline and with 90% or more protocol adherence. Protocol adherence will be defined as the use of the allocated therapy in the intervention group for 6 hours for 3 days (or interruption of methylene blue if the patient does not require a vasoactive drug anymore). Justified interruptions will not be considered violations.

    Time frame: 28 days after randomization.

Secondary outcomes

  1. Capillary refill time

    Serial capillary refill time from randomization up to 72 hours later.

    Time frame: 72 hours after randomization.

  2. Serum lactate level

    Serial measurements of serum lactate level during the 72 hours after randomization.

    Time frame: 72 hours after randomization.

  3. Arteriovenous carbon dioxide difference (gapCO2)

    Serial measurements of arteriovenous carbon dioxide difference (gapCO2) during 72h after randomization.

    Time frame: 72h after randomization.

  4. Central venous oxygen saturation (SvO2)

    Serial measurements of central venous oxygen saturation (SvO2) during 72h after randomization.

    Time frame: 72h after randomization.

  5. Serial measurements of heart rate

    Serial measurements of heart rate from randomization up to 72 hours later.

    Time frame: 72 hours after randomization.

  6. Serial measurements of mean arterial pressure

    Serial measurements of mean arterial pressure from randomization up to 72 hours later.

    Time frame: 72 hours after randomization.

  7. Serial measurements of pulse pressure

    Serial measurements of pulse pressure from randomization up to 72 hours later.

    Time frame: 72 hours after randomization.

  8. Serial measurements of systolic arterial pressure

    Serial measurements of systolic arterial pressure from randomization up to 72 hours later.

    Time frame: 72 hours after randomization.

  9. Serial measurements of dyastolic arterial pressure

    Serial measurements of dyastolic arterial pressure from randomization up to 72 hours later.

    Time frame: 72 hours after randomization.

  10. Methylene blue-related adverse events

    Incidence of adverse events during the three days of administration of methylene blue and up to 28 days after.

    Time frame: 28 days after randomization.

Other outcomes

  1. Variations in the Sequential Organ Failure Assessment-2 Score (SOFA-2)

    Daily SOFA-2 score pontuatin from enrollment to 72 hours later. The SOFA score ranges from 0 to 24, being 24 the worst pontuation, indicating multiple organ dysfunction.

    Time frame: From enrollment to 72 hours later.

  2. Time to vasopressor discontinuation

    Time to complete vasopressor discontinuation from the enrollment up to 28 days.

    Time frame: 28 days after randomization.

  3. Vasopressor dose (norepinephrine and vasopressin)

    Vasopressor dose (norepinephrine and vasopressin) before and after the start of MB infusion, measuring before and after the methylene blue on the first, second, and third days of infusion.

    Time frame: 72 hours after randomization.

  4. Time to weaning from mechanical ventilation

    Total number of days to wean from mechanical ventilation during the 28 days after randomization.

    Time frame: 28 days after randomization.

  5. Need for renal replacement therapy (RRT)

    Total number of days of renal replacement therapy (RRT) during 28 days after randomization.

    Time frame: 28 days after randomization.

  6. Intensive care unit length of stay

    Total number of days until intensive care unit discharge.

    Time frame: 28 days after randomization.

  7. 28-day mortality

    All-cause mortality at day 28 after randomization.

    Time frame: 28 days after randomization.

07

Study locations

1 of 1 sites recruiting
  • Irmandade da Santa Casa de Misericórdia de Curitiba
    Curitiba, Paraná 80010-030, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Nov 2026, 10 months after the start.

Of 13 phase 2/3 interventional studies under Shock, Septic, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 4, 2025
StartActual
Jan 9, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07264543
Lead sponsor
Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva
Collaborators
Irmandade da Santa Casa de Misericordia de Curitiba
Responsible party
Bruna Cassia Dal Vesco (Clinical Research Fellow, Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva) — Principal investigator
First posted
Dec 4, 2025
Start date
Jan 9, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 27, 2026

Study contacts

Bruna Dal Vesco
Contact
brunadalvesco@gmail.com
+55 (41) 3362-6633
Álvaro Réa-Neto
study chair · CEPETI - Centro de Estudos e Pesquisa em Emergências Médicas e Terapia Intensiva

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methylene Blue

Start the discussion